NASDAQ:SAGE Sage Therapeutics (SAGE) News Today $59.54 +2.84 (+5.01%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$56.46▼$59.6850-Day Range$40.65▼$59.5452-Week Range$30.67▼$59.68Volume1.00 million shsAverage Volume407,608 shsMarket Capitalization$3.56 billionP/E RatioN/ADividend YieldN/APrice Target$51.54 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Media Mentions By Week SAGE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼1.020.90▲Average Medical News Sentiment SAGE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼64▲SAGE Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRBC Capital Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)markets.businessinsider.com - June 10 at 1:18 AMJPMorgan Chase & Co. Has $53.88 Million Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - June 9 at 5:36 AMSage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conferencefinance.yahoo.com - June 5 at 10:12 AMVictory Capital Management Inc. Sells 12,636 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - June 5 at 5:28 AMSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by Capital Fund Management S.A.marketbeat.com - June 4 at 7:38 AMHRT Financial LP Has $783,000 Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - June 2 at 6:25 AMFinepoint Capital LP Sells 47,548 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - May 31 at 2:06 PM15 Most Suicidal States in Americafinance.yahoo.com - May 31 at 10:24 AMDimensional Fund Advisors LP Purchases 242,969 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - May 29 at 5:25 AMAnalysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $52.83americanbankingnews.com - May 26 at 2:16 AMSage Therapeutics (NASDAQ:SAGE) PT Raised to $61.00americanbankingnews.com - May 25 at 3:24 AMB of A Securities Maintains Sage Therapeutics (SAGE) Buy Recommendationmsn.com - May 23 at 11:49 PMSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by Thrivent Financial for Lutheransmarketbeat.com - May 23 at 4:51 AMSage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of "Hold" by Analystsmarketbeat.com - May 23 at 2:50 AMSAGE Therapeutics (SAGE) Receives a Buy from Bank of America Securitiesmarkets.businessinsider.com - May 23 at 1:08 AMSage Therapeutics (NASDAQ:SAGE) Coverage Initiated at StockNews.comamericanbankingnews.com - May 22 at 8:32 AMCambridge Investment Research Advisors Inc. Purchases Shares of 36,431 Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - May 19 at 5:27 AMElizabeth Barrett At Sage Therapeutics Tops Up Holding By US$51k \finance.yahoo.com - May 18 at 8:02 AMSage Therapeutics (NASDAQ:SAGE) Research Coverage Started at StockNews.commarketbeat.com - May 18 at 3:52 AMBank of America Securities Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)markets.businessinsider.com - May 15 at 9:22 AMElizabeth Barrett Acquires 1,000 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) Stockamericanbankingnews.com - May 14 at 7:00 AMMorgan Stanley Maintains Sage Therapeutics (SAGE) Equal-Weight Recommendationmsn.com - May 11 at 5:10 PMSage Therapeutics (NASDAQ:SAGE) Upgraded to "Hold" at StockNews.comamericanbankingnews.com - May 11 at 6:00 AMSage Therapeutics (NASDAQ:SAGE) Raised to "Hold" at StockNews.commarketbeat.com - May 10 at 1:33 AMSage Therapeutics: Mid-2023 Data Readout And Possible FDA Approval Make This A Must Watchmsn.com - May 9 at 9:18 AMTD Asset Management Inc Cuts Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - May 9 at 5:25 AMFinancial Analysis: Sage Therapeutics (NASDAQ:SAGE) versus Mereo BioPharma Group (NASDAQ:MREO)americanbankingnews.com - May 9 at 3:22 AMWedbush Equities Analysts Increase Earnings Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE)americanbankingnews.com - May 7 at 1:40 AMAnalysts Offer Predictions for Sage Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:SAGE)americanbankingnews.com - May 7 at 1:40 AMRoyal Bank of Canada Increases Sage Therapeutics (NASDAQ:SAGE) Price Target to $63.00americanbankingnews.com - May 6 at 6:34 AMFY2026 EPS Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE) Reduced by HC Wainwrightamericanbankingnews.com - May 6 at 5:14 AMHC Wainwright Equities Analysts Decrease Earnings Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE)americanbankingnews.com - May 6 at 5:14 AMSage Therapeutics, Inc. Expected to Post Q2 2023 Earnings of ($2.55) Per Share (NASDAQ:SAGE)americanbankingnews.com - May 5 at 6:50 AMSage Therapeutics, Inc. Forecasted to Earn Q2 2023 Earnings of ($2.54) Per Share (NASDAQ:SAGE)americanbankingnews.com - May 5 at 6:50 AMHC Wainwright Weighs in on Sage Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:SAGE)marketbeat.com - May 5 at 6:46 AMSage Therapeutics (NASDAQ:SAGE) Rating Increased to Hold at StockNews.comamericanbankingnews.com - May 5 at 2:56 AMSage Therapeutics (NASDAQ:SAGE) Lifted to Hold at StockNews.comamericanbankingnews.com - May 4 at 4:00 AMCitigroup Maintains Sage Therapeutics (SAGE) Neutral Recommendationmsn.com - May 3 at 8:05 PMRBC Capital Maintains Sage Therapeutics (SAGE) Outperform Recommendationmsn.com - May 3 at 8:05 PMAnalysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and ChitogenX (OtherCHNXF)markets.businessinsider.com - May 3 at 3:05 PMHC Wainwright & Co. Reiterates Sage Therapeutics (SAGE) Neutral Recommendationmsn.com - May 3 at 3:05 PMSAGE Therapeutics (SAGE) Receives a Hold from H.C. Wainwrightmarkets.businessinsider.com - May 3 at 10:04 AMBrokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $52.58americanbankingnews.com - May 3 at 4:02 AMSage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimatesmsn.com - May 2 at 9:42 AMSage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progressfinance.yahoo.com - May 2 at 9:42 AMSage Therapeutics Q1 2023 Earnings Previewseekingalpha.com - May 1 at 5:17 PMSage Therapeutics's Earnings Outlookmsn.com - May 1 at 12:17 PMPostpartum Depression Therapeutics Market Top Key Players by 2031marketwatch.com - April 28 at 8:11 AMSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Recommendation of "Hold" from Brokeragesmarketbeat.com - April 28 at 2:55 AMDual COVID and mental health pandemics are wreaking havoc on Americans. When it comes to the latter, ‘the worst may still be to come’fortune.com - April 26 at 9:08 PM Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Axsome Therapeutics News Today Zai Lab News Today PTC Therapeutics News Today ImmunoGen News Today Maravai LifeSciences News Today Blueprint Medicines News Today Reata Pharmaceuticals News Today Amicus Therapeutics News Today Cytokinetics News Today Galapagos News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:SAGE) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.